^
Association details:
| Biomarker: | CD73 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + uliledlimab (TJD5) (CD73 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.
Published date:
05/19/2021
Excerpt:
Uliledlimab was administered intravenously...alone in the first cycle and in combination with atezolizumab (1,200 mg Q3W) starting on week 4.... CD73 was expressed on 78% (mean) of malignant cells from archival tumor specimens in responders compared to 23% in non-responders.
DOI:
10.1200/JCO.2021.39.15_suppl.2511
Trial ID:
